Pharmacotherapy for adverse events reduces the length of hospital stay in patients admitted to otolaryngology ward: A single arm intervention study

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Suzuki, Akio ^a   Kobayashi, Ryo ^a   Okayasu, Shinji ^a   Kuze, Bunya ^b   Aoki, Mitsuhiro ^a,b   Mizuta, Keisuke ^b   Itoh, Yoshinori ^a  

^a GIFU UNIVERSITY HOSPITAL   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN TANNATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; AZULENE; BROTIZOLAM; CALCIUM CHANNEL BLOCKING AGENT; CEFTRIAXONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUNITRAZEPAM; GRANULOCYTE COLONY STIMULATING FACTOR; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; LOCAL ANESTHETIC AGENT; LOPERAMIDE; MAGNESIUM OXIDE; METOCLOPRAMIDE; NARCOTIC ANALGESIC AGENT; OLANZAPINE; PARACETAMOL; PHOSPHORUS; PICOSULFATE SODIUM; PROTON PUMP INHIBITOR; QUETIAPINE; RISPERIDONE; SODIUM; STEROID; SULTAMICILLIN; TRAMADOL; UNINDEXED DRUG; ZOLPIDEM;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER PAIN; CHEMORADIOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DELIRIUM; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; ELECTROLYTE DISTURBANCE; FEMALE; GASTROINTESTINAL DISEASE; HIGH RISK PATIENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; INTERVENTION STUDY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; NURSE; ODYNOPHAGIA; ORAL MUCOSITIS; OTOLARYNGOLOGIST; OTORHINOLARYNGOLOGY; PAIN; PHARMACIST; RADIATION DERMATITIS; RISK FACTOR; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; KAPLAN MEIER METHOD; MIDDLE AGED; OTORHINOLARYNGOLOGIC DISEASES; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT;

ADULT; AGED; CHEMORADIOTHERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; MALE; MIDDLE AGED; OTORHINOLARYNGOLOGIC DISEASES; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT;

EID: 84920137660     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115879     Document Type: Article

References (27)

1. Vincent C, Neale G, Woloshynowych M (2001) Adverse events in British hospitals: preliminary retrospective record review. BMJ 322: 517-9.
2. Baker GR, Norton PG, Flintoft V, Blais R, Brown A, et al. (2004) The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. CMAJ 170: 1678-86.
3. Landrigan CP, Parry GJ, Bones CB, Hackbarth AD, Goldmann DA, et al. (2010) Temporal trends in rates of patient harm resulting from medical care. N Engl J Med 363: 2124-34.
4. Parmentier-Decrucq E, Poissy J, Favory R, Nseir S, Onimus T, et al. (2013) Adverse events during intrahospital transport of critically ill patients: incidence and risk factors. Ann Intensive Care 3: 10.
5. Howard HH, Barnes BA, Brennan TA, Laird NM, Lawthers AG, et al. (1989) A study of medical injury and medical malpractice. N Eng J Med 324: 370-376.
6. Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, et al. (1991) Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Eng J Med 324: 370-376.
7. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP (1997) Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277: 301-6.
8. Forster AJ, Kyeremanteng K, Hooper J, Shojania KG, van Walraven C (2008) The impact of adverse events in the intensive care unit on hospital mortality and length of stay. BMC Health Serv Res 8: 259.
9. Kaushal R, Bates DW, Franz C, Soukup JR, Rothschild JM (2007) Costs of adverse events in intensive care units. Crit Care Med 35: 2479-83.
10. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, et al. (1997) The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 277: 307-11.
11. Evans RS, Pestotnil SL, Classen DC, Bass SB, Burke JP (1992) Prevention of adverse drug events through computerized surveillance. Proc Annu Symp Comput Appl Med Care 437-41.
12. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, et al. (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29: 4189-98.
13. Mercadante S (2010) Management of cancer pain. Intern Emerg Med 5 Suppl 1: S31-5.
14. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, et al. (2012) American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic noncancer pain: Part 2 - guidance. Pain Physician 15: S67-116.
15. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, et al. (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109: 820-31.
16. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, et al. (2013) Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 70(6): 540-8.
17. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, et al. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24: 3187-205.
18. Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, et al. (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22: 2918-26.
19. National Comprehensive Cancer Network (NCCN) (2011) Clinical Practice Guideline in Oncology v.l.2011. Adult Cancer Pain. Available: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
20. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, et al. (2013) Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA 173: 2039-46.
21. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, et al. (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19: 2201-5.
22. Schilling MB, Parks C, Deeter RG (2011) Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med 2: 859-866.
23. Kronenberger MB, Meyers AD (1994) Dysphagia following head and neck cancer surgery. Dysphagia 9: 236-44.
24. Shune SE, Karnell LH, Karnell MP, Van Daele DJ, Funk GF (2012) Association between severity of dysphagia and survival in patients with head and neck cancer. Head Neck 34: 776-84.
25. Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, et al. (2007) Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68: 1289-98.
26. Kulbersh BD, Rosenthal EL, McGrew BM, Duncan RD, McColloch NL, et al. (2006) Pretreatment, preoperative swallowing exercises may improve dysphagia quality of life. Laryngoscope 116: 883-6.
27. Watanabe T, Ishihara M, Matsuura K, Mizuta K, Itoh Y (2010) Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. Int J Cancer 127: 1984-90.